Charted
Wednesday, Nov. 18, 2026The business of health, by the numbers
Live trackersDeal tracker $7.07B raisedFDA clearances 293 510(k)s in OctoberForm D raises $839M in 30 daysNew trials 266 Phase 2/3 in 30 days
Deals·Virtual Incision

Virtual Incision reports $35.1M stock sale, but only about $4M is new cash

A Form D filed Oct. 5 shows the maker of the MIRA surgical robot sold $35.1 million of a planned $80.1 million offering, almost all of it from converted notes. The company has not announced the round.

Charted Staff3 min read
From an SEC Form D filed Oct. 5, 2026, an earlier Form D/A filed May 6, 2025, and company announcements
A person in a surgical gown holds Virtual Incision's MIRA Surgical System.
A person in a surgical gown holds Virtual Incision's MIRA Surgical System.Courtesy of Virtual Incision
Amount
$35.1M
Type
Private placement
Company
Virtual Incision
Sector
Medtech
Announced
Oct. 5, 2026

Virtual Incision's newest securities filing carries a headline number of $35.1 million. Only about $4 million of it is fresh cash.

The Lincoln, Neb., maker of the MIRA surgical robot sold $35.1 million in equity in a new private offering, according to a Form D filed with the Securities and Exchange Commission on Oct. 5. In a note on the filing, the company broke that into about $4.02 million of new money and $31.12 million from converting convertible notes into stock.

Why it matters: Most of the $35.1 million reflects notes that investors already held being turned into stock, not new funding, and the filing does not show how Virtual Incision is paying for its next phase. The company won FDA clearance in August to use MIRA in benign hysterectomy and has said it will announce when that use becomes commercially available.

The filing puts the total offering at $80.1 million, leaving about $45 million unsold. It lists Sept. 18 as the date of first sale and says 60 investors took part, all accredited. The offering is not expected to last more than a year, and the company reported no sales commissions or finder's fees.

No company announcement of the financing could be found. The company's online newsroom lists no funding news since 2023.

What the filing leaves out

A Form D is a brief notice of a private sale of securities that is exempt from SEC registration. Virtual Incision's does not say when the notes were issued, who holds them, what price or class of stock they converted into, or whether the offering is part of a named series. It names no lead investor, gives no valuation and does not say how the money will be used. The company checked "decline to disclose" for revenue.

An earlier filing, a Form D/A from May 2025, shows Virtual Incision had sold about $7.9 million of a planned $25 million offering of debt securities to 62 investors, with a first sale in March 2025. The filings do not say whether those securities were among the notes that converted.

The new Form D lists James M. Alecxih as an executive officer and director; he signed as chief executive. The company named him CEO in June 2025, after the earlier filing, and the two filings list different executive officers and partly different boards. Robert Larid is listed as an executive officer, and Tyler Stowater, Fernando Pacheco, Amy Kobe and Shahryar Oveissi as directors.

The robot

Virtual Incision says MIRA weighs about two pounds and is designed to work in a standard operating room rather than one set aside for a mainframe robot. The Food and Drug Administration granted MIRA De Novo authorization in February 2024 for adults undergoing colectomy, according to the company. On Aug. 25, 2026, the company said the FDA had cleared MIRA through the 510(k) pathway for benign hysterectomy.

At that time, Virtual Incision said MIRA was commercially available in the U.S. for colectomy and that it would announce timing for gynecology availability later. It described its approach to adding indications as staged.

Its last announced financing was a $30 million extension in September 2023 that brought its Series C to $76 million. Existing investors Bluestem Capital, Endeavour Vision, Baird Capital, cultivate(MD) Capital Funds and PrairieGold Venture Partners led that extension, and Arboretum Ventures and InVivium Capital joined as new investors, according to the company.

What to watch

The next signals are a launch date for MIRA in gynecology and any further sales from the roughly $45 million left in the offering.

Stories bylined Charted Staff are produced by the Charted newsroom from public documents: company announcements, SEC filings, FDA databases and federal rules. Each one lists the documents it was drawn from. Drafted with automated tools from the sources listed with this story and checked against them before publishing. How we report.

More Deals

More
Newsletter

Charted Daily

The day's deals, FDA decisions and policy moves, by the numbers. Free. Sign up now to get the first edition.

No spam. Unsubscribe any time.